Cargando…

Design of phase 2 study of TAS-115, a novel oral multi-kinase inhibitor, in patients with idiopathic pulmonary fibrosis

BACKGROUND: TAS-115, a novel multi-kinase inhibitor, demonstrated antifibrotic effects in vitro and in vivo. METHODS: This is an open-label, intra-patient comparison, exploratory phase 2 study of TAS-115 to evaluate the efficacy and safety in idiopathic pulmonary fibrosis (IPF) patients when orally...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishioka, Yasuhiko, Homma, Sakae, Okubo, Takahito, Azuma, Arata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390536/ https://www.ncbi.nlm.nih.gov/pubmed/34471721 http://dx.doi.org/10.1016/j.conctc.2021.100832

Ejemplares similares

Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis
por: Inomata, Minoru, et al.
Publicado: (2015)

Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2019)

Reply to Horita and Takeshi: Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial
por: Kondoh, Yasuhiro, et al.
Publicado: (2020)

Efficacy and safety of TAS-115, a novel oral multi-kinase inhibitor, in osteosarcoma: an expansion cohort of a phase I study
por: Kawai, Akira, et al.
Publicado: (2021)

Reply to Kobayashi et al.: Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis
por: Kondoh, Yasuhiro, et al.
Publicado: (2020)

Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan
por: Ogura, Takashi, et al.
Publicado: (2023)

Idiopathic Pulmonary Fibrosis: Treatment and Prognosis
por: Fujimoto, Hajime, et al.
Publicado: (2016)

Determinants of Six-Minute Walk Distance in Idiopathic Pulmonary Fibrosis and Idiopathic Pleuroparenchymal Fibroelastosis
por: Sato, Naofumi, et al.
Publicado: (2022)

Fatal diffuse alveolar haemorrhage mimicking acute exacerbation in idiopathic pulmonary fibrosis treated with nintedanib
por: Sugino, Keishi, et al.
Publicado: (2017)

Benefits of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Drug Treatment
por: Iwanami, Yuji, et al.
Publicado: (2022)

Therapeutic Role of Recombinant Human Soluble Thrombomodulin for Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Isshiki, Takuma, et al.
Publicado: (2019)

Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapy
por: Shibutani, Toshihiro, et al.
Publicado: (2023)

Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
por: Sugino, Keishi, et al.
Publicado: (2021)

New risk scoring system for predicting 3-month mortality after acute exacerbation of idiopathic pulmonary fibrosis
por: Sakamoto, Susumu, et al.
Publicado: (2022)

The Activities of Daily Living after an Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Koyama, Kazuya, et al.
Publicado: (2017)

Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma
por: Yamada, Shutaro, et al.
Publicado: (2017)

TAS‐115 inhibits PDGFRα/AXL/FLT‐3 signaling and suppresses lung metastasis of osteosarcoma
por: Yasuda, Naohiro, et al.
Publicado: (2020)

Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis
por: Kondoh, Yasuhiro, et al.
Publicado: (2022)

Irreversible covalent Bruton’s tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial
por: Takeuchi, Tsutomu, et al.
Publicado: (2023)

Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
por: Bendell, Johanna C., et al.
Publicado: (2015)

Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment
por: Azuma, Arata, et al.
Publicado: (2011)

Identification of targetable kinases in idiopathic pulmonary fibrosis
por: Higo, Hisao, et al.
Publicado: (2022)

Xenon-Enhanced Dual-Energy CT Imaging in Combined Pulmonary Fibrosis and Emphysema
por: Sugino, Keishi, et al.
Publicado: (2017)

Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
por: Bendell, Johanna C., et al.
Publicado: (2015)

Association of serum high-mobility group box protein 1 level with outcomes of acute exacerbation of idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia
por: Shimizu, Hiroshige, et al.
Publicado: (2018)

Optimizing antidotal treatment with the oral HSP90 inhibitor TAS-116 against hydrochloric acid-induced pulmonary fibrosis in mice
por: Solopov, Pavel A., et al.
Publicado: (2022)

Shieldings: TAS
Publicado: (2004)

Shieldings: TAS
Publicado: (2004)

Association of serum monomeric periostin level with outcomes of acute exacerbation of idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia
por: Shimizu, Hiroshige, et al.
Publicado: (2021)

Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan
por: Minegishi, Yuji, et al.
Publicado: (2020)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)
por: Richeldi, Luca, et al.
Publicado: (2023)

Primary ciliary dyskinesia caused by a large homozygous deletion including exons 1–4 of DRC1 in Japanese patients with recurrent sinopulmonary infection
por: Keicho, Naoto, et al.
Publicado: (2019)

Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2022)

New Era of Management Concept on Pulmonary Fibrosis with Revisiting Framework of Interstitial Lung Diseases
por: Azuma, Arata, et al.
Publicado: (2020)

Pathological characteristics in idiopathic nonspecific interstitial pneumonia with emphysema and pulmonary hypertension
por: Sugino, Keishi, et al.
Publicado: (2013)

Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis
por: Inomata, Minoru, et al.
Publicado: (2014)

Prognostic Factors in the Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Retrospective Single-center Study
por: Atsumi, Kenichiro, et al.
Publicado: (2017)

Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan
por: Ikeda, Kimiyuki, et al.
Publicado: (2020)

The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial
por: Taniguchi, Hiroyuki, et al.
Publicado: (2011)

Memristive phase switching in two-dimensional 1T-TaS(2) crystals
por: Yoshida, Masaro, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_08m6be6li807lhk5kcvesdpa08